廣告
香港股市 已收市

  • 恒指

    16,224.14
    -161.73 (-0.99%)
     

  • 國指

    5,746.61
    -57.25 (-0.99%)
     

  • 上證綜指

    3,065.26
    -8.96 (-0.29%)
     

  • 滬深300

    3,541.66
    -28.14 (-0.79%)
     

  • 美元

    7.8331
    +0.0019 (+0.02%)
     

  • 人民幣

    0.9238
    +0.0001 (+0.01%)
     

  • 道指

    37,933.77
    +158.39 (+0.42%)
     

  • 標普 500

    4,996.12
    -15.00 (-0.30%)
     

  • 納指

    15,448.85
    -152.65 (-0.98%)
     

  • 日圓

    0.0504
    +0.0000 (+0.06%)
     

  • 歐元

    8.3553
    +0.0209 (+0.25%)
     

  • 英鎊

    9.7270
    -0.0120 (-0.12%)
     

  • 紐約期油

    83.32
    +0.59 (+0.71%)
     

  • 金價

    2,408.10
    +10.10 (+0.42%)
     

  • Bitcoin

    64,594.70
    +659.94 (+1.03%)
     

  • CMC Crypto 200

    1,373.99
    +61.36 (+4.91%)
     

CureVac Files COVID-19 Vaccine Patent Infringement Lawsuit Against BioNTech

Vandana Singh
·1 分鐘文章

  • CureVac N.V. (NASDAQ: CVAC) has moved to assert its intellectual property rights, accumulated over two decades of pioneering work in mRNA technology, which contributed to COVID-19 vaccine development.

  • CureVac has filed a lawsuit in the German Regional Court in Düsseldorf against BioNTech SE (NASDAQ: BNTX) and two of its subsidiaries, seeking fair compensation for infringement of a portfolio of CureVac’s intellectual property rights utilized in Comirnaty, BioNTech and Pfizer Inc’s (NYSE: PFE) mRNA COVID-19 vaccine.

  • Related: CureVac - GSK Start Dosing In Next-Gen COVID-19 Vaccine Candidate Trial.

  • CureVac does not seek an injunction nor intend to take legal action that impedes the production, sale, or distribution of Comirnaty by BioNTech and its partner Pfizer.

  • The CureVac intellectual property portfolio protects multiple inventions considered essential to the design and development of BioNTech’s SARS CoV-2 mRNA vaccine, among others.

  • These relate to the engineering of mRNA molecules, including sequence modifications to increase stability and enhance protein expression and mRNA vaccine formulations specific to SARS CoV-2 vaccines.

  • Price Action: BNTX shares are down 5.17% at $149.35 during the premarket session on the last check Tuesday.

See more from Benzinga

廣告

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.